Analysts Issue Forecasts for ACAD Q1 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for ACADIA Pharmaceuticals in a report released on Thursday, November 6th. HC Wainwright analyst A. Fein expects that the biopharmaceutical company will post earnings of $0.12 per share for the quarter. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ Q2 2026 earnings at $0.20 EPS, Q3 2026 earnings at $0.24 EPS, FY2027 earnings at $2.54 EPS, FY2028 earnings at $2.74 EPS and FY2029 earnings at $2.89 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.14 by $0.28. ACADIA Pharmaceuticals had a return on equity of 14.69% and a net margin of 21.80%.The business had revenue of $278.63 million during the quarter, compared to the consensus estimate of $276.52 million. During the same quarter last year, the company earned $0.20 EPS. ACADIA Pharmaceuticals’s revenue was up 11.3% on a year-over-year basis. ACADIA Pharmaceuticals has set its FY 2025 guidance at EPS.

Several other brokerages also recently issued reports on ACAD. Wall Street Zen downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, September 5th. TD Cowen lifted their target price on shares of ACADIA Pharmaceuticals from $35.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, September 11th. Deutsche Bank Aktiengesellschaft set a $29.00 target price on ACADIA Pharmaceuticals in a report on Thursday, September 25th. JPMorgan Chase & Co. dropped their price target on ACADIA Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a report on Monday, September 29th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of ACADIA Pharmaceuticals in a research note on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $28.94.

ACADIA Pharmaceuticals Stock Performance

Shares of NASDAQ:ACAD traded down $0.01 on Friday, hitting $21.64. The stock had a trading volume of 203,297 shares, compared to its average volume of 2,152,439. ACADIA Pharmaceuticals has a twelve month low of $13.40 and a twelve month high of $26.65. The firm’s 50 day moving average price is $22.69 and its 200-day moving average price is $21.84. The company has a market capitalization of $3.65 billion, a price-to-earnings ratio of 16.32, a price-to-earnings-growth ratio of 7.90 and a beta of 0.80.

Insider Transactions at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, Director Elizabeth A. Garofalo sold 1,600 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $25.98, for a total transaction of $41,568.00. Following the transaction, the director directly owned 25,382 shares in the company, valued at approximately $659,424.36. This represents a 5.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Mark C. Schneyer sold 22,000 shares of ACADIA Pharmaceuticals stock in a transaction on Monday, August 18th. The stock was sold at an average price of $25.18, for a total value of $553,960.00. Following the sale, the executive vice president directly owned 40,130 shares of the company’s stock, valued at approximately $1,010,473.40. This trade represents a 35.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 27,098 shares of company stock worth $678,256. Corporate insiders own 26.50% of the company’s stock.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ACAD. GAMMA Investing LLC boosted its stake in ACADIA Pharmaceuticals by 627.3% in the 1st quarter. GAMMA Investing LLC now owns 3,513 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 3,030 shares during the period. Amalgamated Bank lifted its holdings in shares of ACADIA Pharmaceuticals by 757.7% in the first quarter. Amalgamated Bank now owns 35,002 shares of the biopharmaceutical company’s stock valued at $581,000 after purchasing an additional 30,921 shares in the last quarter. New York State Teachers Retirement System boosted its position in shares of ACADIA Pharmaceuticals by 547.9% during the first quarter. New York State Teachers Retirement System now owns 33,625 shares of the biopharmaceutical company’s stock worth $559,000 after buying an additional 28,435 shares during the period. Principal Financial Group Inc. grew its holdings in shares of ACADIA Pharmaceuticals by 425.2% during the first quarter. Principal Financial Group Inc. now owns 754,748 shares of the biopharmaceutical company’s stock worth $12,536,000 after buying an additional 611,054 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in ACADIA Pharmaceuticals by 96.3% in the 1st quarter. Bank of New York Mellon Corp now owns 804,390 shares of the biopharmaceutical company’s stock valued at $13,361,000 after buying an additional 394,640 shares during the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.